BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for SAB Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-12-04 4:33 pm Purchase | 2023-11-22 | 13G | SAB Biotherapeutics, Inc. SABS | BIOTECHNOLOGY VALUE FUND L P | 917,828 9.990% | 917,828 (New Position) | Filing |